Current standard treatment for HR+ breast cancer primarily relies on endocrine therapy, including selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs)4, 5. The gene discussed is ESR1; the disease is breast carcinoma.